Literature DB >> 15699373

Limb apraxia in corticobasal degeneration and progressive supranuclear palsy.

Paola Soliveri1, Sylvie Piacentini, Floriano Girotti.   

Abstract

OBJECTIVE: Corticobasal degeneration (CBD) and progressive supranuclear palsy (PSP) share pathologic features, and cortical and subcortical signs. Apraxia is frequently described in CBD and sometimes in PSP; however, it is difficult to distinguish ideomotor from limb-kinetic apraxia, and apraxia frequency is unclear. The authors set out to clarify the nature and frequency of apraxia in these diseases.
METHODS: The authors compared probable CBD and PSP patients, matched for motor disability, to healthy age-matched controls on cognitive tests and the De Renzi ideomotor apraxia test.
RESULTS: Cognitive impairment was similar, but more CBD (70.8%) than PSP (36%) patients had apraxia. CBD patients committed more apraxic errors of awkwardness and were more compromised on simple gestures; PSP patients committed more sequence errors.
CONCLUSIONS: While progressive supranuclear palsy (PSP) patients had ideomotor apraxia, the peculiar gesture compromise in corticobasal degeneration (CBD) suggests that limb-kinetic apraxia is dominant. In both illnesses, the movement production system of Roy and Square appears compromised: in CBD defective control of muscle activation seems likely, producing clumsy movements; in PSP, control of motor program activation appears defective, resulting in sequence errors and perseverations. The De Renzi test can reliably estimate apraxia frequency and may be used to distinguish limb-kinetic from ideomotor apraxia.

Entities:  

Mesh:

Year:  2005        PMID: 15699373     DOI: 10.1212/01.WNL.0000150732.92567.BA

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  13 in total

1.  Cognitive-behavioural features of progressive supranuclear palsy syndrome overlap with frontotemporal dementia.

Authors:  Christopher Kobylecki; Matthew Jones; Jennifer C Thompson; Anna M Richardson; David Neary; David M A Mann; Julie S Snowden; Alexander Gerhard
Journal:  J Neurol       Date:  2015-02-07       Impact factor: 4.849

Review 2.  Extrapyramidal syndromes in frontotemporal degeneration.

Authors:  Andrew Kertesz; Paul McMonagle; Sarah Jesso
Journal:  J Mol Neurosci       Date:  2011-09-02       Impact factor: 3.444

Review 3.  The Cognitive Profile of Atypical Parkinsonism: A Meta-Analysis.

Authors:  Simona Raimo; Mariachiara Gaita; Maria Cropano; Giusi Mautone; Alfonsina D'Iorio; Luigi Trojano; Gabriella Santangelo
Journal:  Neuropsychol Rev       Date:  2022-08-12       Impact factor: 6.940

Review 4.  Update on apraxia.

Authors:  Rachel Goldmann Gross; Murray Grossman
Journal:  Curr Neurol Neurosci Rep       Date:  2008-11       Impact factor: 5.081

Review 5.  A model-based approach to understanding apraxia in Corticobasal Syndrome.

Authors:  Vessela Stamenova; Eric A Roy; Sandra E Black
Journal:  Neuropsychol Rev       Date:  2008-12-11       Impact factor: 7.444

6.  Patient care and management of frontotemporal lobar degeneration.

Authors:  Lauren Massimo; Murray Grossman
Journal:  Am J Alzheimers Dis Other Demen       Date:  2008 Apr-May       Impact factor: 2.035

7.  Association of ideomotor apraxia with frontal gray matter volume loss in corticobasal syndrome.

Authors:  Edward D Huey; Matteo Pardini; Alyson Cavanagh; Eric M Wassermann; Dimitrios Kapogiannis; Salvatore Spina; Bernardino Ghetti; Jordan Grafman
Journal:  Arch Neurol       Date:  2009-10

8.  Apraxia in progressive nonfluent aphasia.

Authors:  Jonathan Daniel Rohrer; Martin N Rossor; Jason D Warren
Journal:  J Neurol       Date:  2009-11-12       Impact factor: 4.849

9.  Clinical profile of PiB-positive corticobasal syndrome.

Authors:  James R Burrell; Michael Hornberger; Victor L Villemagne; Christopher C Rowe; John R Hodges
Journal:  PLoS One       Date:  2013-04-05       Impact factor: 3.240

10.  Apraxia and motor dysfunction in corticobasal syndrome.

Authors:  James R Burrell; Michael Hornberger; Steve Vucic; Matthew C Kiernan; John R Hodges
Journal:  PLoS One       Date:  2014-03-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.